Last updated: 02/19/2019 12:30:32

N. meningitidis carriage study

GSK study ID
114991
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Neisseria meningitidis carriage study
Trial description: This carriage study aims to evaluate the presence of meningococcus in Asian populations (and potential for disease) and explore the extent and serogroup distribution of meningococci circulating in the population.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Assessing the carriage prevalence of N.meningitidis using posterior pharyngeal swabs

Timeframe: At enrollment (Day 0)

Secondary outcomes:

The serogroup (determined by Polymerase Chain Reaction) of any isolated N. Meningitidis colonies

Timeframe: At enrollment (Day 0)

Further characterization of any carried N. meningitidis using Multi Locus Sequence Typing

Timeframe: At enrollment (Day 0)

Interventions:
  • Procedure/surgery: Posterior pharyngeal swab
  • Other: Data collection
  • Enrollment:
    1000
    Primary completion date:
    2014-25-03
    Observational study model:
    Case-Only
    Time perspective:
    Cross-Sectional
    Clinical publications:
    Gonzales ML et al. (2017) Meningococcal carriage in children and young adults in the Philippines: a single group, cross-sectional study. Epidemiol Infect. 145(1):126–132.
    Medical condition
    Infections, Meningococcal
    Product
    GSK2647155A
    Collaborators
    Not applicable
    Study date(s)
    August 2013 to March 2014
    Type
    Observational
    Phase
    Not applicable

    Participation criteria

    Sex
    Female & Male
    Age
    5 - 24 years
    Accepts healthy volunteers
    Yes
    • Subjects who the investigator believes can and will comply with the requirements of the protocol or subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.
    • Written informed consent obtained from the subject/from the parent(s)/LAR of the subject.
    • Subjects who have received a meningococcal conjugate vaccine.
    • Use of any investigational or non-registered product within one week before the enrollment visit.

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Manila, Philippines
    Status
    Study Complete

    Study documents

    Scientific result summary
    Available language(s): English
    Protocol
    Available language(s): English

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    2014-25-03
    Actual study completion date
    2014-25-03

    Plain language summaries

    Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

    Additional information about the trial

    Participate in clinical trial
    Additional information
    Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
    Click here
    Access to clinical trial data by researchers
    Visit website